中新健康丨康方生物明星双抗数据不及预期?回应来了

中国新闻网
Yesterday

4月28日, 康方生物 召开线上业务沟通会回应“OS期中数据”争议。消息层面,此前,康方生物发布公告称,依沃西单抗第二个适应症获得国家药监局(NMPA)的批准上市。这个新适应症为,单药用于PD-L1阳性(TPS≥1%)的表皮生长因子受体(EGFR)基因突变阴性和间变性淋巴瘤激酶(ALK)阴性的局部晚期或转移性非小细胞肺癌(NSCLC)的一线治疗。康方生物称,依沃西一线治疗PD-L1阳性NSCLC新...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10